50 related articles for article (PubMed ID: 30553168)
1. Acid sphingomyelinase: No potential as a biomarker for multiple sclerosis.
Leurs CE; Lopes Pinheiro MA; Wierts L; den Hoedt S; Mulder MT; Eijlers AJC; Schoonheim MM; Balk LJ; Uitdehaag BMJ; Killestein J; de Vries HE
Mult Scler Relat Disord; 2019 Feb; 28():44-49. PubMed ID: 30553168
[TBL] [Abstract][Full Text] [Related]
2. Ceramide and Its Related Neurochemical Networks as Targets for Some Brain Disorder Therapies.
Brodowicz J; Przegaliński E; Müller CP; Filip M
Neurotox Res; 2018 Feb; 33(2):474-484. PubMed ID: 28842833
[TBL] [Abstract][Full Text] [Related]
3. Plasma sphingolipids, lung function and COPD: the Cardiovascular Health Study.
Gharib AR; Jensen PN; Psaty BM; Hoofnagle AN; Siscovick D; Gharib SA; Sitlani CM; Sotoodehnia N; Lemaitre RN
ERJ Open Res; 2023 Mar; 9(2):. PubMed ID: 37020834
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis and cancer incidence: A Danish nationwide cohort study.
Nørgaard M; Veres K; Didden EM; Wormser D; Magyari M
Mult Scler Relat Disord; 2019 Feb; 28():81-85. PubMed ID: 30576846
[TBL] [Abstract][Full Text] [Related]
5. Several household chemical exposures are associated with pediatric-onset multiple sclerosis.
Mar S; Liang S; Waltz M; Casper TC; Goyal M; Greenberg B; Weinstock-Guttman B; Rodriguez M; Aaen G; Belman A; Barcellos LF; Rose J; Gorman M; Benson L; Candee M; Chitnis T; Harris Y; Kahn I; Roalsted S; Hart J; Lotze T; Moodley M; Ness J; Rensel M; Rubin J; Schreiner T; Tillema JM; Waldman A; Krupp L; Graves JS; Waubant E;
Ann Clin Transl Neurol; 2018 Dec; 5(12):1513-1521. PubMed ID: 30564618
[TBL] [Abstract][Full Text] [Related]
6. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.
Chitnis T; Gonzalez C; Healy BC; Saxena S; Rosso M; Barro C; Michalak Z; Paul A; Kivisakk P; Diaz-Cruz C; Sattarnezhad N; Pierre IV; Glanz BI; Tomic D; Kropshofer H; Häring D; Leppert D; Kappos L; Bakshi R; Weiner HL; Kuhle J
Ann Clin Transl Neurol; 2018 Dec; 5(12):1478-1491. PubMed ID: 30564615
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a brief electronic screening test for cognitive impairment in multiple sclerosis (SCI-MS Test).
Meca-Lallana JE; Prieto-González JM; Jimenez-Veiga J; Carreón-Guarnizo E; Jiménez-Martín I; Hernández-Clares R; Sistiaga-Berrondo A; Carles-Dies R; García-Molina E; Cerdán-Sánchez M; Costa-Arpín E; Croitoru I; Castillo-Triviño T; Iniesta-Martinez F; García-Pérez E; Olascoaga-Urtaza J
Mult Scler Relat Disord; 2019 Feb; 28():50-56. PubMed ID: 30553169
[TBL] [Abstract][Full Text] [Related]
8. What Causes Deep Gray Matter Atrophy in Multiple Sclerosis?
Schoonheim MM; Geurts JJG
AJNR Am J Neuroradiol; 2019 Jan; 40(1):107-108. PubMed ID: 30591510
[No Abstract] [Full Text] [Related]
9. Predicting clinical progression in multiple sclerosis after 6 and 12 years.
Dekker I; Eijlers AJC; Popescu V; Balk LJ; Vrenken H; Wattjes MP; Uitdehaag BMJ; Killestein J; Geurts JJG; Barkhof F; Schoonheim MM
Eur J Neurol; 2019 Jun; 26(6):893-902. PubMed ID: 30629788
[TBL] [Abstract][Full Text] [Related]
10. Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.
Gasperini C; Prosperini L; Tintoré M; Sormani MP; Filippi M; Rio J; Palace J; Rocca MA; Ciccarelli O; Barkhof F; Sastre-Garriga J; Vrenken H; Frederiksen JL; Yousry TA; Enzinger C; Rovira A; Kappos L; Pozzilli C; Montalban X; De Stefano N;
Neurology; 2019 Jan; 92(4):180-192. PubMed ID: 30587516
[TBL] [Abstract][Full Text] [Related]
11. Vaccines and disease-modifying treatments.
Waubant E; Giovannoni G; Hawkes C; Levy M
Mult Scler Relat Disord; 2018 Nov; 26():A1-A2. PubMed ID: 30573174
[No Abstract] [Full Text] [Related]
12. A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries.
Saida T; Yamamura T; Kondo T; Yun J; Yang M; Li J; Mahadavan L; Zhu B; Sheikh SI
BMC Neurol; 2019 Jan; 19(1):5. PubMed ID: 30616596
[TBL] [Abstract][Full Text] [Related]
13. Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up.
Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
Front Neurol; 2018; 9():1071. PubMed ID: 30581413
[TBL] [Abstract][Full Text] [Related]
14. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A
PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361
[TBL] [Abstract][Full Text] [Related]
15. A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs.
Bowen JD; Kozma CM; Grosso MM; Phillips AL
Mult Scler J Exp Transl Clin; 2018; 4(4):2055217318819031. PubMed ID: 30574342
[TBL] [Abstract][Full Text] [Related]
16. Acid sphingomyelinase as a pathological and therapeutic target in neurological disorders: focus on Alzheimer's disease.
Choi BJ; Park MH; Jin HK; Bae JS
Exp Mol Med; 2024 Feb; 56(2):301-310. PubMed ID: 38337058
[TBL] [Abstract][Full Text] [Related]
17. Lipid signatures of chronic pain in female adolescents with and without obesity.
Gonzalez PA; Simcox J; Raff H; Wade G; Von Bank H; Weisman S; Hainsworth K
Lipids Health Dis; 2022 Aug; 21(1):80. PubMed ID: 36042489
[TBL] [Abstract][Full Text] [Related]
18. Sapropterin (BH4) Aggravates Autoimmune Encephalomyelitis in Mice.
Schmitz K; Trautmann S; Hahnefeld L; Fischer C; Schreiber Y; Wilken-Schmitz A; Gurke R; Brunkhorst R; Werner ER; Watschinger K; Wicker S; Thomas D; Geisslinger G; Tegeder I
Neurotherapeutics; 2021 Jul; 18(3):1862-1879. PubMed ID: 33844153
[TBL] [Abstract][Full Text] [Related]
19. Distinctive sphingolipid patterns in chronic multiple sclerosis lesions.
Podbielska M; Szulc ZM; Ariga T; Pokryszko-Dragan A; Fortuna W; Bilinska M; Podemski R; Jaskiewicz E; Kurowska E; Yu RK; Hogan EL
J Lipid Res; 2020 Nov; 61(11):1464-1479. PubMed ID: 32769146
[TBL] [Abstract][Full Text] [Related]
20. Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods.
van Kruining D; Luo Q; van Echten-Deckert G; Mielke MM; Bowman A; Ellis S; Oliveira TG; Martinez-Martinez P
Adv Drug Deliv Rev; 2020; 159():232-244. PubMed ID: 32360155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
